Business Context and Reporting Period
This Form 8-K Current Report was filed by AntriaBio, Inc. (not Rezolute, Inc.) on November 14, 2013. The filing discloses the entry into a material definitive agreement involving a short-term debt instrument and associated equity warrants.
Key Financial Metrics and Transaction Details
- Debt Instrument: 14% Promissory Note with a principal amount of $250,000.
- Lender: Konus Advisory Group, Inc.
- Equity Component: One common share purchase warrant issued for every dollar borrowed (250,000 total warrants).
- Warrant Terms: Exercise price of $1.25 per share; expiration date of five years from issuance.
- Revenue/Profit/Cash Flow: The filing text does not provide a clear value for revenue, profit, cash flow, or operating margins.
- Liquidity: The filing text does not provide a clear value for total cash, liquidity ratios, or existing debt levels outside of this new note.
Material Changes and Terms
The primary material change is the creation of a new direct financial obligation. The repayment terms are structured as follows:
- Maturity Date: The principal is due at the earlier of:
- November 1, 2014.
- Ten days after the closing of an equity financing that raises at least $3,000,000.
- Interest Rate: 14% per annum.
- Registration Status: The Note and Warrants were issued unregistered, relying on Section 4(a)(2) and Rule 506 exemptions for accredited investors.
Outlook, Risks, and Management Commentary
- Financing Trigger: The debt structure implies an active pursuit of an equity financing round of at least $3 million to trigger early repayment.
- Dilution Risk: The issuance of 250,000 warrants at a $1.25 exercise price represents potential future dilution to existing shareholders.
- Contingencies: Repayment is contingent on either a fixed date or the successful completion of a specific equity financing event.
- Management Commentary: The filing contains no qualitative management commentary or forward-looking statements beyond the transaction terms.
Investor Verification Checklist
- Verify the company's current cash position to assess the ability to service the 14% interest and principal repayment by November 2014.
- Confirm the status of any ongoing equity financing efforts targeting the $3 million threshold.
- Review the full text of Exhibit 10.1 for any prepayment penalties or additional covenants not summarized in the 8-K.
- Calculate the potential dilution impact of the 250,000 warrants relative to the current share count.